# Gastro-oesophageal Reflux Disease and PPI Therapy in 2022

#### Dr Yusuf Moolla

MBChB (Pret), FCP (SA), Master of Medicine (UKZN), Dip HIV MAN (SA), Dip Geriatric Med (SA), Cert. Gastroenterology (SA)

Specialist Physician/Gastroenterologist

Gateway Centre for Lung and Gastrointestinal disease



#### Overview

- Epidemiology
- Pathophysiology
- Phenotypes
- Diagnostic Investigations
- Management
- PPI Refractory GERD
- New PPI Agent



ck

Sunday 17th July Morning

#### **Definition**


 GERD is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications.

The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. AGA

In clinical practice,

Symptoms of heartburn, mild symptoms occurring 2 or more days per week, or moderate to severe occurring 1 or more days per week, are considered as troublesome.

## **Epidemiology**



- Increasing Global prevalence.
- GERD Symptoms are common but vary geographically.
- The highest prevalence of GERD symptoms occurred in one Central American study (19.6%) whereas the lowest prevalence was observed in Asia (10.0%)
- No clear associations
  between GERD symptoms
  with race, age and sex.

## **Epidemiology**


- No consistent evidence for a genetic association with GERD symptoms.
- Smokers >> Non smokers
- Current drinkers > non drinkers
- NSAID users >>> non-users
- Positively associated with increased consumption of fat, sweets, chocolate, and salt & inversely associated with fruit and fibre.




## **Epidemiology**

- No evidence of carbonated beverages promoting GERD.
- More pH- verified supine reflux after a late evening meal.
- Moderate, regular aerobic exercise is inversely associated with GERD symptoms. By contrast, physical activity at work, for example, in a stooped posture, and strenuous exercise, such as weightlifting are positively associated with the presence of GERD symptoms.
- Obesity is a strong risk factor for GERD
- A meta- analysis of trials of *H. pylori* eradication found that the risk of GERD symptoms was not increased after eradication of *H. pylori*


## **Pathophysiology**




## **GERD Phenotypes**









#### **GERD**: Extra-Oesophageal Manifestations

#### Laryngeal

Cough, laryngitis, sub-glottic stenosis, globus, laryngeal cancer, vocal cord granuloma, vocal cord irritation, vocal cord polyps and post-nasal drip

#### Oropharyngeal

Dental erosion, pharyngitis, sore or burning throat, gingivitis and halitosis

#### Ears and sinuses

Earaches, otitis media and sinusitis

#### Pulmonary

Chronic bronchitis, pneumonia, aspiration, bronchiectasis, asthma and idiopathic pulmonary fibrosis

#### Cardiac


Arrhythmia, angina and myocardial infarction

#### Sleep

Sleep apnoea, sleep deprivation, insomnia, snoring, nightmare and sleep disturbance

GERD, gastro-oesophageal reflux disease.

## Diagnostic Investigations is commonly




diagnosed based on the response to empiric acid suppressive therapy or on objective findings

- Diagnostic tests are reserved for patients that continue to be symptomatic or need surgery.
- Visual alterations, or device to determine

## Diagnostic Investigations


#### **Endoscopy**

- Warning symptoms( dysphagia, weight loss, haematemesis, vomiting?)
- Chronic GERD at risk of Barretts
- Suspect disorders: EOE, infection, pill injury...
- Poor response to therapy.
- Require Surgery



## **Diagnostic Investigat**

- For GERD Diagnosis: Visual Alterations to confirm GERD
- Presence of oesophagitis is a strong indicator for GERD.
- Gastroscopy is normal in 2/3 patients






## **Diagnostic Investigations**

#### **Barium**

- Sensitivity: 67% and specificity 47
- Should not be done for the diagno



#### Management:

**Lifestyle and Dietary Changes** 





- Evidence: Weight loss, elevation of head of the bed, and avoid eating at least 3 hrs before bedtime.
- There is limited/no evidence for other lifestyle recommendations.

## Management: Pharmacological

#### **Antacids**

- Not shown to heal EE or prevent complications of GERD.
- Safe (E.g. Al-hydroxide, Mag-hydroxide, Calcium carbonate, Sodium bicarbonate.
- Alginate: More likely to resolve GERD symptoms than placebo or other antacid
- Sulcralfate: Better than placebo in NERD, Limited in healing EE
- Consider Adding to once daily PPI, helped to control breakthrough symptoms

## Management: Pharmacological

#### **H2 Receptor Antagonists**

- Could be consider in NERD, or those low grade EE, on demand therapy for patient with mild disease due to rapid action.
- Consider in patients that are poorly responsive to double dose PPI
- H2RA are commonly added at bedtime to suppressive the effect of night time histamine driven surge of gastric acid secretion.
- It can relieve postprandial heartburn for up to 12 hrs.
- Tachyphylaxis is common and develop with chronic use.

· Other: Potassium Acid Blockers, Baclofen, Prokinetics

## Management: Pharmacological

Proton Pump Inhibitors

Numerous studies: PPi are superior to H2RA in symptom control, mucosal healing and prevention of relapse of GERD

#### **Gold Standard For GERD!**

#### Simple Algorithm of GERD Therapy

Lifestyle Modifications and On Demand Antacids



Intermittent PPI



PPI Daily (and Optimise)



PPI BD (and consider further tests - Refer)



Refractory PPI

• 6 Mistakes with PPI Use...

## Management: PPI Therapy


#### Mistake 1



#### Prescribing a PPI without instructions for use

- PPi can only bind and inhibit active proton-pumps H/K ATPase
- Proton-pumps become active during eating, and not all pumps become active at once
  - PPI need to be in plasma when pumps become active- during eating
  - Ingestion 30min before meals

## **Management: PPI Therapy**



#### Mistake 2

#### Considering the PPI test to be accurate for GERD diagnosis

- Consider 24hr Ph measurement as the gold standard for GERD,
   PPI test is not ideal in studies. Low sensitivity and sensitivity.
- NB: other conditions can respond to PPI e.g gastric ulcer low specificity

## Management: PPI Thera

Mistake 3



## Increasing PPI for persistent heartburn when there is no evidence for GERD

- PPI non-responders often do not have GERD
- ? is the diagnosis of GERD correct
- Symptoms are poor predictors of GERD.
   NB sensitivity of clinical history in the diagnosis of GERD 55%

## **Management: PPI Therapy**

#### Mistake 4



#### Withholding PPI Rx due to fear of complications

? Pneumonia, Fracture, C.Diff diarrhea, Clopidogrel interactions, CKD, Dementia, Gastric Cancer,

Mortality...

- •Compass trail NEMJ: No significant in mortality with pantoprazole Vs placebo.
- •Moayyedi Gastro 2019, Slightly higher chance of enteric infections...

AGA statement. "Much of the evidence linking PPI use to serious long term adverse consequence is weak and insubstantial. It should not deter prescribers from using appropriate doses of PPI for the appropriate indication

## **Management: PPI Therapy**

# 12 3s² Nagnesium 24.305

#### Mistake 5

Not taking hypomagnesemia seriously in PPI users


- Severe < 0.5 (Rare < 0.01)
- Mechanism unclear
- Class affect.
- Stop PPI H2 antagonist, surgery

Management: PPI The

Mistake 6


Stopping PPI Rx due to fundic gland pol


- 2% pop common
- Can be associated with syndromes/ Mostly sporadic
- 4x risk in chronic PPI users
- No risk of dysplasia/cancer



## Management: Surgery?

- Medical therapy -unsatisfactory or undesirable.
- Side effects to therapy
- Poor compliance to therapy
- Large hiatal hernia
- Regurgitation as a predominant symptom
- EE despite max PPIs






 Types: Fundoplication, Magnetic sphincter augmentation device – LINX, Roux and Y: Morbid obese patients and GERD

## **Management: Surgery**

- As effective as medical therapy,? studies superior in controlling GERD symptoms.
- More effective than adding medical therapy – (Baclofen to PPI bd. In patient with GERD with true PPI refractory heartburn)
- Side Effects: Bloating, dysphagia, re-operation.

Predictors of Successful Surgery:

- Typical GERD
- Symptomatic response to PPI
- Abnormal PH and Normal Scope




A. The fundus is wrapped around the back side of the esophagus

B. The wrap is secured with sutures to anchor lower esophagus below diaphragm

## Management: Endoscopic

Alternatives to Surgery


- Stretta procedure: low power, temperature-controlled radiofrequency energy at OGJ.
- Transoral incisionless fundoplication
- Medigus Ultrasonic Surgical Endostapler




## New PPI Agent: Dexilant

- DEXILANT® (dexlansoprazole modified-release capsules) is the first new Proton Pump inhibitor to be launched in South Africa since the launch of esomeprazole.
- It has a unique delivery system allows dual release of the active ingredient in the duodenum and the small intestine.
- It achieves two peak concentrations at various times, within two and five hours of administration.
- Ensures the longest maintenance of drug concentration in the plasma of all known proton pump inhibitors
- Dexlansoprazole modified-release inhibits both basal and stimulated gastric acid secretion.

## New PPI Agent: Dexilant





# New PPI Agent : Dexilant vs Esomeprazole

- A comparison of esomeprazole 40 mg and dexlansoprazole modified-release capsule 60 mg, the average 24-hour intragastric pH following a single dose of dexlansoprazole modified-release capsule was higher compared to a single dose of esomeprazole (58 % versus 48 %; P=0.0003)
- NERD Significantly better symptom control
- GERD 24 weeks Similar

## New PPI Agent: Dexilant

- Better optimal dosing, providing 24-hour symptom control for most patients
- With convenience and flexibility regardless of food or timing of food/dose
- Consistently higher EE healing rates compared with lansoprazole
- High rates of healing are seen across all grades of EE, including moderate-tosevere EE
- Dexlansoprazole is well tolerated
- Safety and tolerability profile similar to lansoprazole

## New PPI Agent: Dexilant

- DEXILANT® is available in two dosage strengths, 30 and 60 mg, and is currently approved for 3 clinical indications: in adults and adolescents,
- Treatment of erosive reflux oesophagitis;
- Maintenance of healed erosive oesophagitis and maintenance of relief of heartburn
- Short-term treatment of heartburn and acid regurgitation associated with symptomatic NERD.



# Indications and Dosage Frequency Extended symptom control 1,2,3

Indication <sup>1</sup> (indicated in patients 12 years of age and older)	Recommended Dose	Frequency	The first
Healing of all grades of erosive oesophagitis (EO)	60 mg	Once-daily for up to 8 weeks	once-a-day PPI with novel dual delayed release technology 1,3
Maintain healing of EO and relief of heartburn	30 mg	Once-daily <sup>t</sup>	
Treating heartburn associated with symptomatic non-erosive gastro-oesophageal reflux disease (GORD)	30 mg	Once-daily for 4 weeks	
	rel <sup>1</sup>	DEXILANT 30 mg  Each capsule contains 30 mg  of dexlansoprazole	60 mg Contains 60 mg

## Take Home Message

- Personalise Therapy and Advice
- Red Flags
- Have a Therapeutic Approach
- Optimise PPI Therapy --- Refer Refractory Cases
- New PPI Agent: Novel Option

# Thank You!

#### Gatewaygidoc@gmail.com



Specialist Physician & Gastroenterologist

MBCHB(PRET), FCP(SA), MMED(UKZN),
DIP HIV MAN(SA), DIP GERIATRIC MED(SA), CERT.GASTROENTEROLOGY(SA)

© GATEWAY PRIVATE HOSPITAL MEDICAL CENTRE

Suite 301, 3rd Floor, 38 Aurora Drive, Umhlanga Ridge, 4319

- +27 31 492 1252
- ✓ drmoolla@gcrgd.co.za

LIFE MOUNT EDGECOMBE
 HOSPITAL

Suite 25, 2nd Floor, 163 Redberry Drive, Phoenix 4068

- +27 31 502 4401
- www.gcrgd.co.za